For the quarter ending 2026-03-31, BTMD had -$18,803K decrease in cash & cash equivalents over the period. $3,540K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | - | 46,408 | - | - |
| Cost of revenue | - | 14,835 | - | - |
| General and administrative | - | 5,114 | - | - |
| Marketing expense | - | 2,586 | - | - |
| Employee-related costs | - | 12,200 | - | - |
| Depreciation and amortization | - | 776 | - | - |
| Other (income) expense, net | - | -1,226 | - | - |
| Income tax expense | - | 2,986 | - | - |
| Other segment items | - | 4,068 | - | - |
| Net income | 2,676 | 2,617 | 9,216 | 19,764 |
| Depreciation and amortization | 980 | 951 | 952 | 1,767 |
| Bad debt (recovery) expense | -433 | 135 | 624 | 962 |
| Amortization of debt issuance costs | 206 | 215 | 206 | 412 |
| Provision for (recovery of) obsolete inventory | -1,118 | 1,092 | -169 | 1,100 |
| Non-cash lease expense | 143 | 140 | 137 | 268 |
| Non-cash interest on share repurchase liability | - | 456 | 742 | 1,986 |
| Share-based compensation expense | 1,758 | 2,198 | 2,410 | 4,313 |
| Gain from change in fair value of earnout liabilities | -2,149 | -1,247 | -2,920 | -8,856 |
| Deferred income taxes | -206 | 2,936 | -246 | 1,285 |
| Accounts receivable | 96 | -969 | -479 | 2,406 |
| Inventory | -301 | 3,710 | 4,145 | -1,613 |
| Other assets | -857 | -42 | -4,039 | 2,387 |
| Accounts payable | 1,410 | 2,467 | 496 | -1,950 |
| Deferred revenue | -344 | -284 | -56 | -60 |
| Accrued expenses | 256 | -1,272 | 2,439 | -3,910 |
| Payments pursuant to tra | 196 | 0 | 0 | 93 |
| Operating lease liabilities | -143 | -136 | -132 | -255 |
| Net cash provided by operating activities | 3,902 | 7,569 | 14,072 | 13,553 |
| Purchases of property and equipment | 362 | 1,077 | 499 | 3,439 |
| Purchases of capitalized software | 806 | 1,287 | 191 | 371 |
| Net cash used in investing activities | -1,168 | -2,364 | -690 | -3,810 |
| Repurchases of class a common stock | 1,071 | 0 | 3,365 | - |
| Borrowings on revolving loans | 7,500 | 5,000 | - | - |
| Repayments on revolving loans | 7,500 | - | - | - |
| Principal repayments on term loan | 1,563 | 1,563 | 1,562 | 3,125 |
| Payments on repurchase liability | 18,500 | 12,500 | 0 | 25,081 |
| Proceeds from exercise of stock options | - | 0 | 0 | 226 |
| Issuance of stock under purchase plan | - | 70 | 0 | 72 |
| Distributions | 405 | 138 | 8 | 1,581 |
| Net cash used in financing activities | -21,539 | -9,131 | -4,935 | -29,489 |
| Effect of exchange rate changes on cash and cash equivalents | 2 | 1 | 0 | 5 |
| Net increase (decrease) in cash and cash equivalents | -18,803 | -3,925 | 8,447 | -19,741 |
| Cash and cash equivalents at beginning of period | 24,123 | 28,048 | 39,342 | - |
| Cash and cash equivalents at end of period | 5,320 | 24,123 | 28,048 | - |
biote Corp. (BTMD)
biote Corp. (BTMD)